237 related articles for article (PubMed ID: 25504005)
1. Peroxisome proliferator-activated receptor-gamma agonists for Alzheimer's disease and amnestic mild cognitive impairment: a systematic review and meta-analysis.
Liu J; Wang LN; Jia JP
Drugs Aging; 2015 Jan; 32(1):57-65. PubMed ID: 25504005
[TBL] [Abstract][Full Text] [Related]
2. Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in patients with stroke or transient ischaemic attack.
Liu J; Wang LN
Cochrane Database Syst Rev; 2015 Oct; (10):CD010693. PubMed ID: 26511368
[TBL] [Abstract][Full Text] [Related]
3. The peroxisome proliferators activated receptor-gamma agonists as therapeutics for the treatment of Alzheimer's disease and mild-to-moderate Alzheimer's disease: a meta-analysis.
Cheng H; Shang Y; Jiang L; Shi TL; Wang L
Int J Neurosci; 2016; 126(4):299-307. PubMed ID: 26001206
[TBL] [Abstract][Full Text] [Related]
4. Pioglitazone for the treatment of Alzheimer's disease.
Galimberti D; Scarpini E
Expert Opin Investig Drugs; 2017 Jan; 26(1):97-101. PubMed ID: 27885860
[TBL] [Abstract][Full Text] [Related]
5. Intravenous immunoglobulins for Alzheimer's disease and mild cognitive impairment due to Alzheimer's disease: A systematic review with meta-analysis.
Liu J; Wang LN
Expert Rev Neurother; 2019 Jun; 19(6):475-480. PubMed ID: 31092051
[No Abstract] [Full Text] [Related]
6. Apolipoprotein E Gene Polymorphisms Affect the Efficacy of Thiazolidinediones for Alzheimer's Disease: A Systematic Review and Meta-Analysis.
Iketani R; Ohno K; Kawasaki Y; Matsumoto K; Yamada H; Kishino S
Biol Pharm Bull; 2018; 41(7):1017-1023. PubMed ID: 29962398
[TBL] [Abstract][Full Text] [Related]
7. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study.
Watson GS; Cholerton BA; Reger MA; Baker LD; Plymate SR; Asthana S; Fishel MA; Kulstad JJ; Green PS; Cook DG; Kahn SE; Keeling ML; Craft S
Am J Geriatr Psychiatry; 2005 Nov; 13(11):950-8. PubMed ID: 16286438
[TBL] [Abstract][Full Text] [Related]
8. Protective Effects of Pioglitazone on Cognitive Impairment and the Underlying Mechanisms: A Review of Literature.
Alhowail A; Alsikhan R; Alsaud M; Aldubayan M; Rabbani SI
Drug Des Devel Ther; 2022; 16():2919-2931. PubMed ID: 36068789
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy and acceptability of antidiabetic agents for Alzheimer's disease and mild cognitive impairment: A systematic review and network meta-analysis.
Cao B; Rosenblat JD; Brietzke E; Park C; Lee Y; Musial N; Pan Z; Mansur RB; McIntyre RS
Diabetes Obes Metab; 2018 Oct; 20(10):2467-2471. PubMed ID: 29790638
[TBL] [Abstract][Full Text] [Related]
10. Current Progress on Peroxisome Proliferator-activated Receptor Gamma Agonist as an Emerging Therapeutic Approach for the Treatment of Alzheimer's Disease: An Update.
Khan MA; Alam Q; Haque A; Ashafaq M; Khan MJ; Ashraf GM; Ahmad M
Curr Neuropharmacol; 2019; 17(3):232-246. PubMed ID: 30152284
[TBL] [Abstract][Full Text] [Related]
11. Effects of Peroxisome Proliferator-Activated Receptor-Gamma Agonists on Cognitive Function: A Systematic Review and Meta-Analysis.
Zhong H; Geng R; Zhang Y; Ding J; Liu M; Deng S; Tu Q
Biomedicines; 2023 Jan; 11(2):. PubMed ID: 36830783
[TBL] [Abstract][Full Text] [Related]
12. Rosiglitazone and pioglitazone for the treatment of Alzheimer's disease.
Miller BW; Willett KC; Desilets AR
Ann Pharmacother; 2011 Nov; 45(11):1416-24. PubMed ID: 22028424
[TBL] [Abstract][Full Text] [Related]
13. Bapineuzumab for mild to moderate Alzheimer's disease: a meta-analysis of randomized controlled trials.
Abushouk AI; Elmaraezy A; Aglan A; Salama R; Fouda S; Fouda R; AlSafadi AM
BMC Neurol; 2017 Apr; 17(1):66. PubMed ID: 28376794
[TBL] [Abstract][Full Text] [Related]
14. [Alzheimer's disease].
Hanyu H; Sato T
Nihon Rinsho; 2010 Feb; 68(2):330-4. PubMed ID: 20158105
[TBL] [Abstract][Full Text] [Related]
15. Possible role of rice bran extract in microglial modulation through PPAR-gamma receptors in alzheimer's disease mice model.
El-Din SS; Abd Elwahab S; Rashed L; Fayez S; Aboulhoda BE; Heikal OA; Galal AF; Nour ZA
Metab Brain Dis; 2021 Oct; 36(7):1903-1915. PubMed ID: 34043126
[TBL] [Abstract][Full Text] [Related]
16. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
Wilding JP
Diabetes Obes Metab; 2012 Nov; 14(11):973-82. PubMed ID: 22443197
[TBL] [Abstract][Full Text] [Related]
17. Multi-Target Neuroprotection of Thiazolidinediones on Alzheimer's Disease via Neuroinflammation and Ferroptosis.
Yang J; Shi X; Wang Y; Ma M; Liu H; Wang J; Xu Z
J Alzheimers Dis; 2023; 96(3):927-945. PubMed ID: 37927258
[TBL] [Abstract][Full Text] [Related]
18. Improvement in long term and visuo-spatial memory following chronic pioglitazone in mouse model of Alzheimer's disease.
Gupta R; Gupta LK
Pharmacol Biochem Behav; 2012 Aug; 102(2):184-90. PubMed ID: 22503969
[TBL] [Abstract][Full Text] [Related]
19. Butyrylcholinesterase K and Apolipoprotein E-ɛ4 Reduce the Age of Onset of Alzheimer's Disease, Accelerate Cognitive Decline, and Modulate Donepezil Response in Mild Cognitively Impaired Subjects.
De Beaumont L; Pelleieux S; Lamarre-Théroux L; Dea D; Poirier J;
J Alzheimers Dis; 2016 Oct; 54(3):913-922. PubMed ID: 27567841
[TBL] [Abstract][Full Text] [Related]
20. An in-silico approach: identification of PPAR-γ agonists from seaweeds for the management of Alzheimer's Disease.
Kotha S; B S; Kulkarni VM; S RS; B HK; R H
J Biomol Struct Dyn; 2021 Apr; 39(6):2210-2229. PubMed ID: 32216605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
